Hepatitis C News and Research

Latest Hepatitis C News and Research

News outlets examine challenges with expanding global child immunization campaigns

Wednesday's release of the WHO, UNICEF and the World Bank joint report on childhood vaccines highlighted gains in recent global vaccination campaigns and also found that nearly 24 million infants worldwide don't get the recommended first-year vaccination.

23 Oct 2009

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the third quarter 2009.

22 Oct 2009

Schering-Plough announces 2009 third quarter financial results

Schering-Plough Corporation (NYSE: SGP) today reported financial results for the 2009 third quarter.

22 Oct 2009

Markers that cause primary liver cancer identified

Hepatocellular carcinoma (HCC) or primary liver cancer forms in the epithelial tissue of the liver and is most commonly caused by the hepatitis B virus (HBV) or hepatitis C virus (HCV). In the U.S., the National Cancer Institute (NCI) estimates that 15,000 men and 6,000 women are diagnosed with HCC each year.

21 Oct 2009

Aethlon Hemopurifier effective in capturing H1N1 Swine Flu Virus

Aethlon Medical, Inc. announced today that research studies have documented the Aethlon Hemopurifier® is effective in capturing the current pandemic strain of the H1N1 Swine Flu Virus. The Hemopurifier® is the first-in-class medical device able to selectively remove infectious viruses and immunosuppressive proteins from the bloodstream.

21 Oct 2009

Interim report from Medivir

Medivir designated another candidate drug (CD), MIV-711 in its osteoporosis portfolio, thus enhancing its commercial opportunities.

21 Oct 2009

Dutch researcher sheds new light on coronaviruses

Using novel techniques, Dutch researcher Matthijs Raaben has cast new light on the replication of coronaviruses, a family of viruses including the cause of SARS. He has shown, using luminescent viruses, how coronaviruses use host cells and how we can use the intracellular processes to attack the virus.

21 Oct 2009

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

A cholera outbreak in Zimbabwe has infected more than 100, resulting in five deaths, state media said Tuesday, Reuters reports, "raising fears of a repeat of last year's epidemic that claimed more than 4,000 lives.

21 Oct 2009

Patients with chronic hepatitis C can benefit by drinking coffee

Patients with chronic hepatitis C and advanced liver disease who drink three or more cups of coffee per day have a 53% lower risk of liver disease progression than non-coffee drinkers according to a new study led by Neal Freedman, Ph.D., MPH, from the National Cancer Institute (NCI).

20 Oct 2009

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

Public health nurses with the Sudbury and District Public Health Unit are going to conciliation in their bid to reach a new contract with their employer. Conciliation dates have been set for November 3 and 4, 2009.

20 Oct 2009

Biomagnetics Diagnostics to raise $1 million

Biomagnetics Diagnostics Corp. (Pink Sheets:BMGP), a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced the completion of its equity financing designed to fund entry into the Integrated Optical Biosensor Systems (IOBS) market.

20 Oct 2009

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

As millions of Americans remain concerned about government-recommended flu shots, dozens of citizens dressed in full haz-mat suits will gather Wednesday, October 21, at the entrance to the Centers For Disease Control (CDC) to greet arriving members of the Advisory Committee on Immunization Practices.

20 Oct 2009

Cangene to acquire U.S. commercialization rights for HepaGam B

Cangene Corporation today announces that it has signed an agreement with its majority shareholder, the Apotex Group, under which Cangene acquires all U.S. commercialization rights for HepaGam B(R) (Hepatitis B Immune Globulin Intravenous (Human)). HepaGam B(R) is Cangene's hepatitis B immune globulin, which is approved for treating two hepatitis-B-related indications in the U.S.

20 Oct 2009

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced the full presentation of results from BLISS-52, the first of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus (SLE).

20 Oct 2009

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

The FDA today approved Cervarix, a new vaccine to prevent cervical cancer and precancerous lesions caused by human papillomavirus (HPV) types 16 and 18. The vaccine is approved for use in girls and women ages 10 years through 25 years.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Human Genome Sciences, Inc. today announced that it has earned a $75 million milestone payment from Novartis, related to successful completion of the Phase 3 development program and the decision to submit applications seeking regulatory approval to market ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C.

19 Oct 2009

Chembio Diagnostics to supply over 2000 PrimaTB STAT-PAK tuberculosis testing kits

Chembio Diagnostics, Inc., which develops, manufactures, markets and licenses point-of-care diagnostic tests, has agreed to provide over 2,000 PrimaTB STAT-PAK tuberculosis (TB) testing kits which are approved for use in Macaques to the Orangutan Conservancy (OC) to support the organization's continued drive to raise the level of veterinary care at orangutan rehabilitation centers.

19 Oct 2009

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

Aethlon Medical, Inc. disclosed today that clinical data resulting from the treatment of Hepatitis-C (HCV) infected patients with the Aethlon Hemopurifier® will be presented at the 42nd Annual Meeting & Scientific Exposition of the American Society of Nephrology (ASN).

15 Oct 2009

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

Ortho Clinical Diagnostics today announced U.S. Food and Drug Administration (FDA) approval of a diagnostic assay for the detection of antibodies to human immunodeficiency virus (HIV) types 1+2 (Anti-HIV 1+2) for use on the VITROS® 5600 Integrated and VITROS® 3600 Immunodiagnostic Systems.

From Ortho-Clinical Diagnostics, Inc. 15 Oct 2009

Hepatitis C News and Research

Latest Hepatitis C News and Research

News outlets examine challenges with expanding global child immunization campaigns

Bristol-Myers Squibb reports strong sales and earnings growth for third quarter 2009

Schering-Plough announces 2009 third quarter financial results

Markers that cause primary liver cancer identified

Aethlon Hemopurifier effective in capturing H1N1 Swine Flu Virus

Interim report from Medivir

Dutch researcher sheds new light on coronaviruses

Also in Global Health News: Cholera in Zimbabwe; personal computers; medical 'outliers'; rain in Kenya; generic drugs

Patients with chronic hepatitis C can benefit by drinking coffee

Sudbury and District Public Health Unit nurses to negotiate with their employer for a new contract

Biomagnetics Diagnostics to raise $1 million

Potential hazards of H1N1 vaccine and seasonal flu shot not disclosed, say protesters

Cangene to acquire U.S. commercialization rights for HepaGam B

Human Genome Sciences and GlaxoSmithKline to present Phase 3 trial results of BENLYSTA

FDA approves GlaxoSmithKline Biologicals' Cervarix for prevention of cervical cancer

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Human Genome Sciences completes Phase 3 development program, earns $75 million from Novartis

Chembio Diagnostics to supply over 2000 PrimaTB STAT-PAK tuberculosis testing kits

Aethlon Medical to present data on HVC patients treated with its Hemopurifier at the 42nd ASN meeting

FDA approves Ortho Clinical Diagnostics' anti-HIV 1+2 test for use on VITROS 5600 & 3600 systems

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Hepatitis C News and Research

Latest Hepatitis C News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in